
News|Articles|August 1, 2005
Dual peroxisome proliferator-activated receptor agonist demonstrates significant lipid benefits
Phase 3 clinical trial results have demonstrated that the dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist muraglitazar achieves significant beneficial lipid effects compared with pioglitazone, and the agent also provides long-term glycemic control in type 2 diabetics. The results were reported during the American Diabetes Association (ADA) 65th Annual Meeting in San Diego, Calif.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
PBM reform. It has finally happened
3
TrumpRx launches; some experts question its long-term value
4
FDA issues draft guidance on MRD and complete response as primary endpoints for accelerated multiple myeloma drug approvals
5

























